Compare CACC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CACC | LNTH |
|---|---|---|
| Founded | 1972 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.7B |
| IPO Year | 1996 | 2014 |
| Metric | CACC | LNTH |
|---|---|---|
| Price | $559.79 | $101.56 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $505.00 | $87.00 |
| AVG Volume (30 Days) | 129.4K | ★ 784.1K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.00 | N/A |
| EPS | ★ 12.40 | 1.80 |
| Revenue | ★ $2,317,200,000.00 | $343,374,000.00 |
| Revenue This Year | $91.73 | N/A |
| Revenue Next Year | $3.58 | $14.19 |
| P/E Ratio | ★ $44.58 | $60.02 |
| Revenue Growth | ★ 7.16 | 3.62 |
| 52 Week Low | $401.90 | $47.27 |
| 52 Week High | $668.86 | $111.86 |
| Indicator | CACC | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 34.61 | 45.27 |
| Support Level | $529.10 | $99.63 |
| Resistance Level | $579.80 | $102.66 |
| Average True Range (ATR) | 22.20 | 3.73 |
| MACD | -11.43 | -0.49 |
| Stochastic Oscillator | 11.76 | 13.90 |
Credit Acceptance Corp is a consumer finance company that specializes in automobile loans. These loans are offered through a U.S. nationwide network of automobile dealers that benefit from sales of vehicles to consumers who could otherwise not obtain financing. The company also benefits from repeat and referral sales, and from sales to customers responding to advertisements for financing, but qualify for traditional financing. The company derives its revenue from finance charges, premiums earned on the reinsurance of vehicle service contracts, and other fees. Of these, financing charges, including servicing fees, are by far a source of revenue.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.